Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 14/20 | 1.00 |
| ▸ | CA1 | P00915 | 13/20 | 1.00 |
| ▸ | CA9 | Q16790 | 9/20 | 1.00 |
| ▸ | CA12 | O43570 | 5/20 | 0.51 |
| ▸ | CA7 | P43166 | 4/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | PNMT | P11086 | 1/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6297784 | 0.90 | CA2 (0.82) | CA2CA1CA9CA12CA7 | |
| SCHEMBL8029327 | 0.86 | CA2 (0.76) | CA2CA1CA9CA12CA7 | |
| SCHEMBL12157402 | 0.83 | CA2 (0.71) | CA2CA1CA9PNMTLMNA | |
| SCHEMBL18029748 | 0.83 | CA2 (0.71) | CA2CA1CA9CA12CA7 | |
| SCHEMBL10154025 | 0.79 | CA1 (0.65) | CA2CA1CA9CA12CA7 | |
| SCHEMBL27546526 | 0.76 | CA1 (0.60) | CA2CA1CA9CA12CA7 | |
| SCHEMBL1155659 | 0.74 | CA9 (0.59) | CA2CA1CA9CA12LMNA | |
| SCHEMBL11132890 | 0.73 | CA2 (0.58) | CA2CA1CA9CA12CA7 | |
| SCHEMBL4011978 | 0.71 | CA1 (0.54) | CA2CA1CA9CA12CA7 | |
| SCHEMBL13547786 | 0.71 | CA1 (0.54) | CA2CA1CA9CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2000063202-A2 | BENZO[b] THIOPHENE SULFONAMIDE-1, 1-DIOXIDE DERIVATIVES AND THEIR USE AS ANTINEOPLASTIC AGENTS | UNIVERSIDAD PUBLICA DE NAVARRA (ES) | 2000-10-26 | — | — | WO | claimed |
| US-20240400502-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | UNIV QUEENSLAND (AU) | 2024-12-05 | — | — | US | disclosed |
| CN-113582889-B | Sulfonylureas and related compounds and uses thereof | 昆士兰大学 | 2024-09-20 | — | — | CN | disclosed |
| US-11845715-B2 | — | — | 2023-12-19 | — | — | US | disclosed |
| US-11845715-B2 | — | — | 2023-12-19 | — | — | US | disclosed |
| US-11845715-B2 | — | — | 2023-12-19 | — | — | US | disclosed |
| US-20220112159-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | UNIV QUEENSLAND (AU) | 2022-04-14 | — | — | US | disclosed |
| EP-3888749-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | The University of Queensland (AU) | 2021-10-06 | — | — | EP | disclosed |
| EP-3888749-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | The University of Queensland (AU) | 2021-10-06 | — | — | EP | disclosed |
| US-11130731-B2 | Sulfonylureas and related compounds and use of same | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2021-09-28 | — | — | US | disclosed |
| US-11130731-B2 | Sulfonylureas and related compounds and use of same | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2021-09-28 | — | — | US | disclosed |
| EP-3578547-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | The University of Queensland (AU) | 2019-12-11 | — | — | EP | disclosed |
| EP-3578547-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | The University of Queensland (AU) | 2019-12-11 | — | — | EP | disclosed |
| US-20180044287-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | INFLAZOME LIMITED (IE) | 2018-02-15 | — | — | US | disclosed |
| US-20180044287-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | INFLAZOME LIMITED (IE) | 2018-02-15 | — | — | US | disclosed |
| US-20180044287-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | INFLAZOME LIMITED (IE) | 2018-02-15 | — | — | US | disclosed |
| WO-2016131098-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-08-25 | — | — | WO | disclosed |
| WO-2000063202-A2 | BENZO[b] THIOPHENE SULFONAMIDE-1, 1-DIOXIDE DERIVATIVES AND THEIR USE AS ANTINEOPLASTIC AGENTS | UNIVERSIDAD PUBLICA DE NAVARRA (ES) | 2000-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112159-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | NLRP3, PYCARD, IAPP | CA2 2434/4885CA1 4141/4885CA9 4136/4885 |
| US-11845715-B2 | — | NLRP3, PYCARD, NOD1 | CA2 3818/4885CA1 4541/4885CA9 4525/4885 |
| US-11130731-B2 | Sulfonylureas and related compounds and use of same | NLRP3, PYCARD, IAPP | CA2 2434/4885CA1 4141/4885CA9 4136/4885 |
| US-20240400502-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | NLRP3, PYCARD, IAPP | CA2 2434/4885CA1 4141/4885CA9 4136/4885 |
| US-20180044287-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | NLRP3, PYCARD, IAPP | CA2 2434/4885CA1 4141/4885CA9 4136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.